Severity
Moderate
ModerateClass IIOngoing
FDA Drug recall · Reported July 8, 2026
Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets), 12.5/1000 mg, 60 Tablets per Bottle, Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 USA. NDC: 00597-0300-45
CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.
Boehringer Ingelheim Pharmaceuticals, Inc. recalled Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets),… - a moderate-severity action.
Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets),… was recalled by Boehringer Ingelheim Pharmaceuticals, Inc. in July 8, 2026. Reason: CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a produc…. Check the official notice for the remedy. Verify recall #D-0657-2026 with the FDA Drug before acting.
The recall
Boehringer Ingelheim Pharmaceuticals, Inc. issued this moderate-severity FDA Drug recall-CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a produc….
- Moderate
- severity level
- Class II
- classification
- July 8, 2026
- reported
Sourced from official FDA Drug enforcement records. Verify recall #D-0657-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
Recall Insight
This FDA Drug action (record #D-0657-2026) was formally reported on July 8, 2026, with the manufacturer initiating the action on June 12, 2026. It is classified under Moderate severity (Class II), with a current status of Ongoing. Boehringer Ingelheim Pharmaceuticals, Inc. is listed as the recalling firm, operating out of Ridgefield, CT. Federal records list the affected scope as 560 bottles.
The documented reason for this recall is: CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product. Distribution data in the federal record shows the product reached: OH. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Children & Baby Products recalls over time
Where this recall sits in its category - 3,772 children & baby products recalls on record
Of 88,001 recalls with an agency hazard classification, 19,020 are high severity, 64,468 moderate, and 4,513 low. A further 16,157 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Affected scope
560 bottles
Related Recalls
6
0 from same agency
Product description
Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets), 12.5/1000 mg, 60 Tablets per Bottle, Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 USA. NDC: 00597-0300-45
Reason for recall
CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.
Recall Profile
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Ongoing |
| Recall number | D-0657-2026 |
| Date reported | July 8, 2026 |
| Date initiated | June 12, 2026 |
| Recalling firm | Boehringer Ingelheim Pharmaceuticals, Inc. |
| Firm location | Ridgefield, CT |
| Affected scope | 560 bottles |
| Distribution | OH |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
- Check the recall number (D-0657-2026) and product description against the item you own. Search the archive
- Confirm the current status with FDA Drug before acting, recall details can be updated.
- Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Frequently Asked Questions
What product was recalled? ▼
Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets), 12.5/1000 mg, 60 Tablets per Bottle, Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 USA. NDC: 00597-0300-45. Recalled by Boehringer Ingelheim Pharmaceuticals, Inc.. Units affected: 560 bottles.
Why was this product recalled? ▼
CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.
Which agency issued this recall? ▼
This recall was issued by the FDA Drug on July 8, 2026. Severity: Moderate. Recall number: D-0657-2026.
Where was the recalled product distributed? ▼
Distribution: OH.
How do I check if my product is affected by a recall? ▼
Check the product description and recall number (D-0657-2026) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device? ▼
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.
Nationwide recalls with similar severity or category timing
Two federal-filing-derived peer sets for this notice, both outside the same recalling firm and filing state so the neighborhoods are not firm or geographic containment.
Similar severity · nearest report date
Same archive severity grade (Moderate), closest by report date among other firms and states.
Similar Children & Baby Products · nearest report date
Same product category, closest by report date among other firms and states (deduped against the severity set).
Nearby Recalls in This Category
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Showing 5 of 4006 other recalls in this category.
CPSC No agency class
A2batt Recalls EEMB Lithium Coin Battery Chargers Due to Risk of Serious Injury or Death from Battery Ingestion; Violat…
EEMB USA, doing business as A2batt, Inc., of Redlands, California · 2026-08-06
CPSC No agency class
Little Rawr Pull String Teething Toys Recalled Due to Risk of Serious Injury or Death from Choking; Violate Mandatory S…
Shenzhen Okabesini Technology Co., Ltd., dba Okabesini-us, of China · 2026-08-06
CPSC No agency class
Play Yard and Crib Mattresses Recalled Due to Risk of Serious Injury or Death from Entrapment and Fire Hazards; Violate…
· 2026-08-06
CPSC No agency class
Wnttmt Baby Walkers Recalled Due to Risk of Serious Injury or Death from Fall and Entrapment Hazards; Violate Mandatory…
Changsha Yuelu District Ruiwu E-Commerce Co., Ltd., dba WURUI.BABY, of China · 2026-08-06
CPSC No agency class
HARPPA Recalls Nordi Toddler Tower Stools Due to Risk of Serious Injury and Death from Entrapment and Fall Hazards
· 2026-07-30
Compare this recall with A2batt Recalls EEMB Lithium Coin Battery Chargers Due to Ri… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported July 8, 2026. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.